Sandoz Group AG Share Price

Equities

SDZ

CH1243598427

Pharmaceuticals

Market Closed - Swiss Exchange 09:00:41 31/05/2024 pm IST 5-day change 1st Jan Change
32.06 CHF +1.04% Intraday chart for Sandoz Group AG +0.12% +18.48%

Financials

Sales 2024 * 1.03TCr 927.7Cr 86TCr Sales 2025 * 1.1TCr 987.59Cr 91TCr Capitalization 1.52TCr 1.37TCr 1,27200Cr
Net income 2024 * 71Cr 64Cr 5.92TCr Net income 2025 * 97Cr 88Cr 8.12TCr EV / Sales 2024 * 1.78 x
Net Debt 2024 * 311.53Cr 280.81Cr 26TCr Net Debt 2025 * 273.17Cr 246.23Cr 23TCr EV / Sales 2025 * 1.64 x
P/E ratio 2024 *
21.8 x
P/E ratio 2025 *
15.6 x
Employees 22,633
Yield 2024 *
1.79%
Yield 2025 *
2.31%
Free-Float 91.29%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.04%
1 week+0.12%
1 month+3.42%
3 months+14.70%
6 months+24.80%
Current year+18.48%
More quotes
1 week
31.44
Extreme 31.44
32.59
1 month
30.06
Extreme 30.06
32.80
Current year
25.33
Extreme 25.33
32.80
1 year
22.70
Extreme 22.7
32.80
3 years
22.70
Extreme 22.7
32.80
5 years
22.70
Extreme 22.7
32.80
10 years
22.70
Extreme 22.7
32.80
More quotes
Date Price Change Volume
31/24/31 32.06 +1.04% 1,999,753
30/24/30 31.73 +0.51% 583,968
29/24/29 31.57 -2.23% 930,222
28/24/28 32.29 -0.68% 595,126
27/24/27 32.51 +1.53% 438,205

Delayed Quote Swiss Exchange, May 31, 2024 at 09:00 pm IST

More quotes
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
35.48 USD
Average target price
39.82 USD
Spread / Average Target
+12.23%
Consensus

Quarterly revenue - Rate of surprise